Published in Int J Oncol on May 01, 2005
Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A (2006) 1.97
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer (2006) 1.32
T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev (2011) 1.21
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol (2014) 1.15
Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer (2011) 1.12
Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res (2009) 1.11
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer (2006) 1.07
Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res Treat (2008) 0.99
Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. Breast Cancer Res (2012) 0.97
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res (2010) 0.96
Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways. Evid Based Complement Alternat Med (2014) 0.94
Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase. J Cell Biochem (2008) 0.92
Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One (2012) 0.92
Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res (2010) 0.91
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer (2011) 0.88
Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2. J Biol Chem (2012) 0.88
RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study. J Exp Clin Cancer Res (2011) 0.87
Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis (2015) 0.86
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer (2008) 0.85
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. Mol Clin Oncol (2014) 0.85
COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J Gastroenterol (2007) 0.84
Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas (2011) 0.83
Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. Breast Cancer Res (2006) 0.83
Down-regulation of LATS kinases alters p53 to promote cell migration. Genes Dev (2015) 0.81
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res (2010) 0.80
Contribution of xanthine oxidoreductase to mammary epithelial and breast cancer cell differentiation in part modulates inhibitor of differentiation-1. Mol Cancer Res (2011) 0.80
Methylation status of COX-2 in blood leukocyte DNA and risk of gastric cancer in a high-risk Chinese population. BMC Cancer (2015) 0.80
Cyclooxygenase-2 expression in primary and recurrent pterygium. Indian J Ophthalmol (2008) 0.79
Lung-derived factors mediate breast cancer cell migration through CD44 receptor-ligand interactions in a novel ex vivo system for analysis of organ-specific soluble proteins. Neoplasia (2014) 0.78
Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget (2016) 0.77
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression. Oncotarget (2015) 0.76
COX-2 dependent regulation of mechanotransduction in human breast cancer cells. Cancer Biol Ther (2015) 0.76
Cox-2 gene overexpression in ureteral stump urothelial carcinoma following nephrectomy for renal cell carcinoma: a case report. J Med Case Rep (2012) 0.75
Role of the Slug Transcription Factor in Chemically-Induced Skin Cancer. J Clin Med (2016) 0.75
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population. Curr Pharmacol Rep (2015) 0.75
Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression. J Cancer Res Clin Oncol (2005) 0.75
Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin. Front Pharmacol (2017) 0.75
Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene (2017) 0.75
Adaptor Protein p62 Promotes Skin Tumor Growth and Metastasis and is Induced by UVA Radiation. J Biol Chem (2017) 0.75
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib. Clin Exp Metastasis (2014) 0.75
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Reduced incidence of breast cancer-related lymphedema following mastectomy and breast reconstruction versus mastectomy alone. Plast Reconstr Surg (2012) 2.13
Assessment of the current Medicare reimbursement system for breast cancer operations. Ann Surg Oncol (2004) 2.07
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer (2010) 1.90
Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer (2009) 1.63
Factors influencing career choice among medical students interested in surgery. Curr Surg (2004) 1.53
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol (2010) 1.45
Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg (2011) 1.42
Inflammatory breast cancer: what we know and what we need to learn. Oncologist (2012) 1.41
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res (2008) 1.33
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res (2013) 1.30
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol (2012) 1.29
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat (2008) 1.28
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist (2011) 1.22
Brief intervention by surgeons can influence students toward a career in surgery. J Surg Res (2003) 1.22
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat (2010) 1.19
Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer (2010) 1.19
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer (2011) 1.19
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer (2003) 1.18
Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol (2010) 1.16
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer (2011) 1.14
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg (2009) 1.13
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer (2010) 1.11
Melanoma adrenal metastasis: natural history and surgical management. Am J Surg (2008) 1.10
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer (2008) 1.10
Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol (2012) 1.09
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol (2011) 1.08
Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res (2008) 1.07
Potential targets to encourage a surgical career. J Am Coll Surg (2005) 1.06
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res (2006) 1.06
A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg (2004) 1.05
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg (2011) 1.05
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg (2006) 1.03
Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol (2012) 1.02
Bortezomib combination therapy in multiple myeloma. Semin Hematol (2012) 1.01
Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol (2010) 0.99
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol (2009) 0.99
Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys (2010) 0.98
Role of cyclooxygenase-2 in breast cancer. J Surg Res (2002) 0.97
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer (2010) 0.95
COX-2 induces IL-11 production in human breast cancer cells. J Surg Res (2006) 0.95
System-like consolidation of olfactory memories in Drosophila. J Neurosci (2013) 0.95
Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer (2010) 0.95
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg (2008) 0.94
Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer (2010) 0.94
Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J (2007) 0.93
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res (2011) 0.93
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol (2010) 0.92
Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One (2012) 0.92
Biofilms. Otolaryngol Clin North Am (2010) 0.91
Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer (2011) 0.91
Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res (2010) 0.91
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat (2015) 0.90
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis (2010) 0.90
Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol (2008) 0.90
Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res (2007) 0.89
Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg (2006) 0.89
Microbiome of the paranasal sinuses: Update and literature review. Am J Rhinol Allergy (2016) 0.89
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys (2012) 0.88
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer (2006) 0.87
Structures of the iron-sulfur flavoproteins from Methanosarcina thermophila and Archaeoglobus fulgidus. J Bacteriol (2005) 0.87
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol (2013) 0.86
Bilateral silent sinus syndrome. Ear Nose Throat J (2012) 0.86
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus (2013) 0.85
Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery (2005) 0.85
Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. Structure (2002) 0.84
Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med (2013) 0.84
Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res (2012) 0.84
Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther (2007) 0.83
Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat (2014) 0.82
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol (2015) 0.82
Atypical dermatofibrosarcoma protuberans in the breast. Breast J (2005) 0.82
Improved postoperative pain control using thoracic paravertebral block for breast operations. Breast J (2009) 0.81
Oncoplastics: techniques for reconstruction of partial breast defects based on tumor location. J Surg Oncol (2011) 0.81
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J (2010) 0.81
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res (2010) 0.80
Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res (2013) 0.80
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat (2012) 0.80
Giant pelvic schwannoma with ancient change. J Am Coll Surg (2003) 0.79
Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res (2012) 0.79
Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer. Ann Surg Oncol (2015) 0.78
Orthopedic surgery implications of breast cancer. Expert Rev Anticancer Ther (2008) 0.78
The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer (2014) 0.78
Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer Biol Ther (2011) 0.77